|
|
基于“肠道菌群”探讨益气健脾法治疗冠心病的临床进展
|
Abstract:
冠心病(CHD)是指冠脉粥样硬化引起冠脉狭窄、痉挛或闭塞，导致心肌缺血缺氧或坏死的心脏疾病。由于国民生活方式改变及其症状的复杂性，冠心病的发病率及病死率正逐年上升。目前西药结合介入治疗冠心病效果显著，但在冠心病早期症状防治、冠脉再狭窄等方面治疗有限。随着中医药现代化研究的深入，许多中医理论与西医机理共性被相继证实，中医药多靶点、多途径为冠心病的防治提供新的契机。近年来，干预肠道菌群防治心脑血管疾病成为心血管领域又一研究方向，同时中医益气健脾法治疗冠心病临床疗效确切，对肠道菌群亦有调节作用。因此基于“肠道菌群”探讨益气健脾法治疗冠心病的机制具有重要研究意义。本文将对益气健脾中药进行综述，主要包括调节脂代谢、抗炎、调节免疫、改善内皮功能、抗氧化应激，探讨“肠道菌群”及益气健脾法共性等多方面治疗冠心病。以期为临床运用益气健脾法治疗冠心病及其现代科学研究提供理论依据。
Coronary heart disease (CHD) means that coronary artery atherosclerosis causes coronary artery stenosis, spasm or occlusion, resulting in myocardial ischemia, hypoxia or necrosis of the heart dis-ease. The incidence and mortality of coronary heart disease are increasing year by year due to the change of national lifestyle and the complexity of symptoms. At present, western medicine com-bined with interventional treatment of coronary heart disease has a significant effect, but in the early symptoms of coronary heart disease prevention and treatment, coronary artery restenosis and other aspects of treatment is limited. With the deepening of TCM modernization research, many similarities between TCM theory and Western medicine mechanism have been confirmed one after another, and the multi-target and multi-approach of TCM provide new opportunities for the preven-tion and treatment of coronary heart disease. In recent years, intervention of intestinal flora to prevent and treat cardiovascular and cerebrovascular diseases has become another research direc-tion in the cardiovascular field. At the same time, the TCM method of invigorating qi and invigorat-ing spleen has a definite clinical effect on coronary heart disease, and also has a regulating effect on intestinal flora. Therefore, it is of great significance to explore the mechanism of invigorating qi and invigorating spleen in the treatment of coronary heart disease based on “intestinal flora”. This arti-cle will review the traditional Chinese medicines for invigorating qi and invigorating spleen, mainly including regulating lipid metabolism, anti-inflammation, regulating immunity, improving endo-thelial function, anti-oxidative stress, exploring “intestinal flora” and the commonness of invigorat-ing qi and invigorating spleen for the treatment of coronary heart disease. The aim is to provide theoretical basis for the clinical application of tonifying qi and invigorating spleen in the treatment of coronary heart disease and modern scientific research.
| [1] | 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(6): 553-578. |
| [2] | 潘杰, 刘来浩, 牟建伟. 肠道菌群与人类健康研究进展[J]. 山东师范大学学报(自然科学版), 2021, 36(4): 337-365. |
| [3] | Tang, W.H., Kitai, T. and Hazen, S.L. (2017) Gut Microbiota in Cardiovascular Health and Disease. Circulation Research, 120, 1183-1196. https://doi.org/10.1161/CIRCRESAHA.117.309715 |
| [4] | 王亚丽, 程艳丽, 商丽华. 肠道菌群在冠心病发病机制中的研究进展[J]. 中国研究型医院, 2023, 10(1): 59-62. |
| [5] | 杨光, 何浩强, 陈光, 王阶. 中药调节肠道菌群干预冠心病及其危险因素的研究进展[J]. 中国中药杂志, 2020, 45(1): 29-36. |
| [6] | Onal, E.M., Afsar, B., Covic, A., Vaziri, N.D. and Kanbay, M. (2019) Gut Microbiota and Inflammation in Chronic Kidney Disease and Their roles in the Development of Cardiovascular Disease. Hypertension Research, 42, 123-140.
https://doi.org/10.1038/s41440-018-0144-z |
| [7] | 高丽娟, 刘立, 李龙龙, 周亚兰, 吕若琳, 周亚楠, 黄生辉. 基于微生物-肠-脑轴的脾胃为后天之本理论探讨[J]. 时珍国医国药, 2019, 30(6): 1449-1450. |
| [8] | 黄湘龙. 冠心病中医证候特征演变规律及其化验指标相关性[D]: [硕士学位论文]. 天津: 天津中医药大学, 2022. |
| [9] | 杨果. 中医健康管理模式下冠心病心绞痛中医证素演变特点的观察性研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2022. |
| [10] | 石伊娜, 陈金锋, 杨波, 等. 雷忠义国医大师论治冠心病痰瘀互结致气虚证的探究[J]. 辽宁中医药大学学报, 2023: 1-15. |
| [11] | Wu, K., Yuan, Y., Yu, H., Dai, X., Wang, S., Sun, Z., Wang, F., Fei, H., Lin, Q., Jiang, H. and Chen, T. (2020) The Gut Microbial Metabolite Trimethylamine N-Oxide Aggravates GVHD by Inducing M1 Macrophage Polarization in Mice. Blood, 136, 501-515. https://doi.org/10.1182/blood.2019003990 |
| [12] | Witkowski, M., Weeks, T.L. and Hazen, S.L. (2020) Gut Microbiota and Cardiovascular Disease. Circulation Research, 127, 553-570. https://doi.org/10.1161/CIRCRESAHA.120.316242 |
| [13] | 孙东文, 姜文君, 邰晓峰, 等. 中西医对肠道菌群与冠心病关系的研究及治疗进展[J]. 吉林中医药, 2023, 43(12): 1488-1492. |
| [14] | 胡海兵, 崔立, 郭靓骅, 王春艳, 华修国, 余强, 尹桂芝. 基于高通量测序技术的冠心病患者肠道菌群多样性研究[J]. 上海交通大学学报(农业科学版), 2016, 34(2): 1-11+19. |
| [15] | 陈扬平, 陈维玉, 张秋霞, 修建成. 不同临床分型冠心病患者的肠道菌群多样性分析[J]. 实用医学杂志, 2020, 36(13): 1754-1758. |
| [16] | Liu, H., Zhuang, J., Tang, P., Li, J., Xiong, X. and Deng, H. (2020) The Role of the Gut Microbiota in Coronary Heart Disease. Current Atherosclerosis Reports, 22, Arti-cle No. 77. https://doi.org/10.1007/s11883-020-00892-2 |
| [17] | Liu, H., Chen, X., Hu, X., Niu, H., Tian, R., Wang, H., Pang, H., et al. (2019) Alterations in the Gut Microbiome and Metabolism with Coronary Artery Disease Severity. Microbiome, 7, Article No. 68.
https://doi.org/10.1186/s40168-019-0683-9 |
| [18] | Warrier, M., Shih, D.M., Burrows, A.C., Ferguson, D., Gromovsky, A.D., Brown, A.L., Marshall, S., et al. (2015) The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Reports, 10, 326-338. https://doi.org/10.1016/j.celrep.2014.12.036 |
| [19] | Zhou, X., Li, J., Guo, J., Geng, B., Ji, W., Zhao, Q., et al. (2018) Gut-Dependent Microbial Translocation Induces Inflammation and Cardiovascular Events after ST-Elevation Myocardial Infarction. Microbiome, 6, Article No. 66.
https://doi.org/10.1186/s40168-018-0441-4 |
| [20] | Tang, W.H.W., Li, D.Y. and Hazen, S.L. (2019) Dietary Metabo-lism, the Gut Microbiome, and Heart Failure. Nature Reviews Cardiology, 16, 137-154. https://doi.org/10.1038/s41569-018-0108-7 |
| [21] | 罗雅亭, 程如越, 梁惠菁, 王家妮, 沈曦, 何方. 高脂饮食对小鼠糖、脂代谢及肠道菌群结构的影响[J]. 营养学报, 2020, 42(5): 458-464. |
| [22] | 李子芃, 陈巍, 田海. 肠道菌群及其代谢产物在冠心病中作用的研究进展[J]. 中国胸心血管外科临床杂志, 2023, 30(5): 761-765. |
| [23] | Heianza, Y., Ma, W., Di Donato, J.A., Sun, Q., Rimm, E.B., Hu, F.B., Rexrode, K.M., Manson, J.E. and Qi, L. (2020) Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk. Journal of the American College of Cardiology, 75, 763-772. https://doi.org/10.1016/j.jacc.2019.11.060 |
| [24] | Senthong, V., Wang, Z., Li, X.S., Fan, Y., Wu, Y., Tang, W.H. and Hazen, S.L. (2016) Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intes-tinal Microbiota in a COURAGE-Like Patient Cohort. Journal of the American Heart Association, 5, e002816.
https://doi.org/10.1161/JAHA.115.002816 |
| [25] | Yao, M.E., Liao, P.D., Zhao, X.J. and Wang, L. (2020) Trime-thylamine-N-Oxide Has Prognostic Value in Coronary Heart Disease: A Meta-Analysis and Dose-Response Analysis. BMC Cardiovascular Disorders, 20, Article No. 7.
https://doi.org/10.1186/s12872-019-01310-5 |
| [26] | Yu, D., Shu, X.O., Rivera, E.S., Zhang, X., Cai, Q., Calcutt, M.W., et al. (2019) Urinary Levels of Trimethylamine- N-Oxide and Incident Coronary Heart Disease: A Prospective Investigation among Urban Chinese Adults. Journal of the American Heart Association, 8, e010606. https://doi.org/10.1161/JAHA.118.010606 |
| [27] | 姜惠卿, 于良生, 赵秀姿. 补中益气汤治疗冠心病104例分析[J]. 齐鲁医学杂志, 2004(4): 348. |
| [28] | 姜华, 杨景明. 参苓白术散对脾虚小鼠肠道功能的影响及其机制研究[J]. 亚太传统医药, 2016, 12(7): 16-17. |
| [29] | 黄文武, 彭颖, 王梦月, 彭崇胜, 李晓波. 四君子汤及其单味药水煎液对脾虚大鼠肠道菌群的调节作用[J]. 中国实验方剂学杂志, 2019, 25(11): 8-15. |
| [30] | 孙巍. 浅谈补中益气汤在促进肠道益生菌生长中的作用[J]. 求医问药(下半月), 2013, 11(9): 137-138. |
| [31] | 汤燕醒. 加味归脾汤治疗气血两虚型冠心病40例疗效观察[J]. 中国实用医药, 2017, 12(19): 112-114. |
